We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Digital Interventions in Neurorehabilitation: iTALKbetter

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04566081
Recruitment Status : Completed
First Posted : September 28, 2020
Last Update Posted : May 23, 2022
Sponsor:
Information provided by (Responsible Party):
University College, London

Brief Summary:

iTALKBetter will provide an app-based therapy for people with word retrieval difficulties who have had a stroke.

This study aims to test the therapy application for people with naming difficulties through a small scale randomized controlled trial.


Condition or disease Intervention/treatment Phase
Stroke Aphasia Anomia Other: iTALKbetter: deterministic Other: iTALKbetter: reactive Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Other
Official Title: Digital Interventions in Neuro-Rehabilitation (DINR): A Digital Neuro Intervention (DNI) for Word Retrieval (Anomia)
Actual Study Start Date : October 14, 2019
Actual Primary Completion Date : February 25, 2022
Actual Study Completion Date : February 25, 2022

Arm Intervention/treatment
Active Comparator: iTALKbetter: deterministic

Participants will receive the deterministic version of the iTALKbetter therapy for 6 weeks. Participants are required to use the therapy for 1.5 hours everyday to reach the required dose of 60 hours over the 6 week period.

iTALKbetter:deterministic version will randomise the order all of the words that are to be trained and participants will cycle through all of these words regardless of their performance until complete at which point the order is re-randomised and participants begin the cycle again.

Other: iTALKbetter: deterministic
A word retrieval therapy application
Other Name: deterministic iTB

Active Comparator: iTALKbetter: reactive

Participants will receive the reactive version of the iTALKbetter therapy for 6 weeks. Participants are required to use the therapy for 1.5 hours everyday to reach the required dose of 60 hours over the 6 week period.

iTALKbetter reactive version is identical to the deterministic version for the first cycle only. From then on the words participants are trained on can change depending on their performance on that word over a number of cycles. Words that participants are failing to retrieve over a number of cycles will be retired from the therapy as they are deemed too difficult for a given participant. Similarly words that are correctly retrieved over a number of consecutive cycles are also retired from the therapy as they are deemed to have been learned. In this way iTALKbetter reactive version will gradually give each participant a personalised corpus of words that they can train on, focusing on the words where they stand to make the most improvements.

Other: iTALKbetter: reactive
A word retrieval therapy application




Primary Outcome Measures :
  1. Change in accuracy performance on a bespoke Word Retrieval Test: WRT [ Time Frame: baseline (week 1), pre intervention (week 12), post-intervention (week 18) ]
    The WRT is custom test of word retrieval comprised of a subset of the trained and untrained items form the iTALKbetter therapy. Participants accuracy on the word retrieval test is measured at multiple timepoints (baseline, pre intervention, during intervention and post intervention).


Secondary Outcome Measures :
  1. Patient and carer reported outcome measures [ Time Frame: pre intervention (week 12), post intervention (week 18) ]
    Qualitative semi-structured interviews to assess a variety of outcomes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Any type of stroke but at least 6 months after onset.
  • Evidence of aphasia on the Comprehensive Aphasia Test
  • English as their dominant language
  • Able to tolerate MRI brain scan
  • Able to give informed consent
  • Able to use the DNI (app)

Exclusion Criteria:

  • No diagnosis of developmental language disorders
  • No diagnosis of severe dementia or primary progressive aphasia
  • No major co-existing neurological or psychiatric diagnosis
  • No contraindications to brain scanner (e.g. the presence of ferromagnetic implants or other metallic or electronic objects in the body, weight over 24 stone, claustrophobia or pregnancy).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04566081


Locations
Layout table for location information
United Kingdom
University College London
London, United Kingdom, WC1E6BT
Sponsors and Collaborators
University College, London
Investigators
Layout table for investigator information
Principal Investigator: Alexander P Leff, Professor University College, London
Layout table for additonal information
Responsible Party: University College, London
ClinicalTrials.gov Identifier: NCT04566081    
Other Study ID Numbers: 18\0071
First Posted: September 28, 2020    Key Record Dates
Last Update Posted: May 23, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University College, London:
Anomia
Word Retrieval
Digital Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Aphasia
Anomia
Speech Disorders
Language Disorders
Communication Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases